Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.

H, Takahashi; T, Kessoku; M, Kawanaka; M, Nonaka; H, Hyogo; H, Fujii; T, Nakajima; K, Imajo; K, Tanaka; Y, Kubotsu; H, Isoda; S, Oeda; O, Kurai; M, Yoneda; M, Ono; Y, Kitajima; R, Tajiri; A, Takamori; A, Kawaguchi; S, Aishima; M, Kage; A, Nakajima; Y, Eguchi; K, Anzai

doi:10.1002/hep4.1696

Public

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.

Shared by NobleBlocks on Jun 17, 2021 • 12:00 AM UTC

Authors:

Takahashi H

Kessoku T

Kawanaka M

Abstract

Sodium glucose cotransporter-2 inhibitors (SGLT2is) are now widely used to treat diabetes, but their effects on nonalcoholic fatty liver disease (NAFLD) remain to be determined. We aimed to evaluate the effects of SGLT2is on the pathogenesis of NAFLD. A multicenter, randomized, controlled trial was ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!